First Bio Lab, LLC

First Bio Lab, LLC was paid $1.55M by Medicaid between Sep 2021 and Nov 2024, across 13 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 56% of everything it billed.

33Billing provider infoFIRST BIO LAB, LLC
IRVINE, CA 92614

33aNPI1386315869assigned 09/23/2021

33bProvider typeClinical Medical Laboratory

28Total paid$1.55M

24GClaims44,861

24DCodes billed13

24AFirst – last monthSep 2021 – Nov 2024

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#167 of 561

Median peer was paid$222K

This provider vs. median7.0×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2021	722	$41K
2022	31,624	$1.02M
2023	9,857	$322K
2024incomplete	2,658	$173K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	56%	15,432	7,065	$874K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	15%	16,574	7,425	$237K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	10%	3,688	1,572	$157K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	7.1%	1,069	496	$111K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	5.3%	1,066	603	$82K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	4.2%	6,087	2,881	$66K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	1.4%	725	448	$22K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	45	45	$3K
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	<1%	116	111	$734.72
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	<1%	14	12	$577.27
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	16	16	$17.69
80053	Comprehensive metabolic panel	<1%	15	15	$16.80

1 more codes

80061

Lipid panel

<1%

$11.54

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTORRES, ASHLIE (CEO)

Same official

Other billing entities under TORRES, ASHLIE

Full network →

Provider	Location	Paid
Aim Laboratories LLC	Bridgeton, MO	$5.05M
Focal Point Laboratories LLC	Mission Viejo, CA	$253K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.